

RECEIVED

JUN 15 2000 PATENTS

## MAILING CERTIFICATION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on August 15, 2000

*B. S. Londa*  
Bruce S. Londa

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty's Docket No: 101195-2

Examiner :

Group Art Unit

Applicant : Margret Hoehe et al.

Appln. No. : 09/582,719

Filed : June 29, 2000

For : Novel Sequence Variants of the Human Beta 2-Adrenergic Gene and Use Thereof

INFORMATION DISCLOSURE STATEMENT

Hon. Assistant Commissioner of Patents  
Washington, D.C. 20231

Dear Sir:

The following sections are being submitted for this Information

Disclosure Statement:

- Sec. 1 - Preliminary Statements
- Sec. 2 - Identification of Time of Filing
- Sec. 4 - Statements with Respect to Listing of Information
- Sec. 6 - Statements with Respect to Copies of Listed  
Information Items Accompanying This Statement

Section 1  
Preliminary Statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56.

While this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56 it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(b) the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists.

Section 2  
Identification of Time of Filing

This Information Disclosure Statement is filed within three months after the filing date of the application.

The art is discussed in the specification of the present application.


Section 4  
Statements with Respect to Listing of Information

A list of the patent(s) and/or publications is set forth on the attached 1 page of Form PTO-1449 (modified).

Section 6  
Statements with Respect to Copies of Listed Information  
Items Accompanying This Statement

A copy of each of the items on PTO-1449 (modified) is supplied  
herewith.

Respectfully Submitted,



---

Bruce S. Londa (33,531)  
Attorney for Applicant  
Norris, McLaughlin & Marcus P.A.  
20 Exchange Place, 37th Floor  
New York, N.Y. 10005  
Telephone: (212) 968-1300  
Facsimile (212) 968-1307

RECEIVED

JUN 15 2001

<b>LIST OF PATENTS AND PUBLICATIONS</b> <b>APPLICANT'S INFORMATION</b> <b>DISCLOSURE STATEMENT</b> (Form PTO-1449 Modified)	Attorney Docket: 101195-2	Serial No. 09/582,719
	Applicant: Margret Hoehe et al.	
	Filing Date: June 29, 2000	Group:

## U.S. PATENT DOCUMENTS

Examiner's Initial		Document Number	Date	Name	Class	Sub Class	Filing Date If appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub Class	Translation Yes No	
	AL							
	AM							
	AN							
	AO							
	AP							

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AR	A. Parola et al.; The Peptide Product of a 5' Leader Cistron in the $\beta$ 2 Adrenergic Recepto mRNA Inhibits Receptor Synthesis; The Journal of Biological Chemistry; Vol. 269, No. 6, Feb. 11, 1994; pgs. 4497-4505
AS	B. Kobilka et al.; cDNA for the human $\beta$ 2-adrenergic receptor: A protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor; Proc. Natl. Acad. Sci. USA. Vol. 84, January 1987; pgs. 46-50
AT	P. Richterich et al.; DNA Sequencing with Direct Transfer Electrophoresis and Nonradioactive Detection; Methods for Sequencing DNA; 1993; pgs. 187-217

EXAMINER:

DATE CONSIDERED:

- **EXAMINER:** Initial if Reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered, include copy of this form with next communication to applicant.
-